🚀 VC round data is live in beta, check it out!
Hamlet BioPharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for Hamlet BioPharma and similar public comparables like Ryvu Therapeutics, Karolinska Development, Fate Therapeutics, Galectin Therapeutics and more.
Hamlet BioPharma Overview
About Hamlet BioPharma
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
Founded
N/A
HQ
Employees
2
Website
Sectors
Financials (FY)
EV
$162M
Hamlet BioPharma Financials
Hamlet BioPharma reported last fiscal year revenue of — and negative EBITDA of ($5M).
In the same fiscal year, Hamlet BioPharma generated ($5M) in EBITDA losses and had net loss of ($6M).
Hamlet BioPharma P&L
In the most recent fiscal year, Hamlet BioPharma reported revenue of — and EBITDA of ($5M).
Hamlet BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($6M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Hamlet BioPharma Stock Performance
Hamlet BioPharma has current market cap of $164M, and enterprise value of $162M.
Market Cap Evolution
Hamlet BioPharma's stock price is $0.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $162M | $164M | -2.9% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHamlet BioPharma Valuation Multiples
Hamlet BioPharma trades at (33.4x) EV/EBITDA.
Hamlet BioPharma Financial Valuation Multiples
As of April 18, 2026, Hamlet BioPharma has market cap of $164M and EV of $162M.
Equity research analysts estimate Hamlet BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Hamlet BioPharma has a P/E ratio of (27.6x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $164M | XXX | $164M | XXX | XXX | XXX |
| EV (current) | $162M | XXX | $162M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (33.4x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (27.0x) | XXX | XXX | XXX |
| P/E | — | XXX | (27.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (38.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Hamlet BioPharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Hamlet BioPharma Margins & Growth Rates
Hamlet BioPharma's revenue in the last fiscal year grew by —.
Hamlet BioPharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.0M for the same period.
Hamlet BioPharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 15% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Hamlet BioPharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Hamlet BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Ryvu Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Karolinska Development | XXX | XXX | XXX | XXX | XXX | XXX |
| Fate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Galectin Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cardiol Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hamlet BioPharma M&A Activity
Hamlet BioPharma acquired XXX companies to date.
Last acquisition by Hamlet BioPharma was on XXXXXXXX, XXXXX. Hamlet BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Hamlet BioPharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHamlet BioPharma Investment Activity
Hamlet BioPharma invested in XXX companies to date.
Hamlet BioPharma made its latest investment on XXXXXXXX, XXXXX. Hamlet BioPharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Hamlet BioPharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Hamlet BioPharma
| Where is Hamlet BioPharma headquartered? | Hamlet BioPharma is headquartered in Sweden. |
| How many employees does Hamlet BioPharma have? | As of today, Hamlet BioPharma has over 2 employees. |
| Is Hamlet BioPharma publicly listed? | Yes, Hamlet BioPharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Hamlet BioPharma? | Hamlet BioPharma trades under HAMLET B ticker. |
| When did Hamlet BioPharma go public? | Hamlet BioPharma went public in 2015. |
| Who are competitors of Hamlet BioPharma? | Hamlet BioPharma main competitors are Ryvu Therapeutics, Karolinska Development, Fate Therapeutics, Galectin Therapeutics. |
| What is the current market cap of Hamlet BioPharma? | Hamlet BioPharma's current market cap is $164M. |
| Is Hamlet BioPharma profitable? | No, Hamlet BioPharma is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.